Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.
You may also be interested in...
GSK Keeps Oncology 2.0 Growth Plans On Track
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Keeping Track: Nektar Withdraws Oxycodegol NDA As Novel Submission Pileup Continues
The latest drug development news and highlights from our US FDA Performance Tracker.
GSK On Track For Six Regulatory Submissions In The Second Half
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.